Guinea-Bissau Suspends US-Backed Hepatitis B Vaccine Study Over Sovereignty Concerns

January 31, 2026 Dr. Michael Lee – Health Editor Health

Here’s a summary of the article, focusing on the key points regarding the hepatitis B vaccine trial in Guinea-Bissau:

* Trial Suspended: A hepatitis B vaccine trial in Guinea-Bissau, led by Danish researchers and involving 14,000 infants, has been suspended by the country’s new Minister of Health, Quinhin Nantote, due to concerns about the scientific review process.
* Ethical Concerns & Study Design: The trial’s design is controversial.It planned to delay the hepatitis B vaccine for half of the infants until six weeks of age, withholding a standard preventative measure. Critics, like Dr. Abdulhammad Babatunde, argue this is unethical, as the control group should receive the standard of care (immediate vaccination). This raises echoes of past unethical medical studies like the Tuskegee experiment.
* Sovereignty & Review: The Africa Centres for Disease control and Prevention (Africa CDC) is assisting guinea-Bissau in reviewing the study,at the request of the Minister of Health.The Africa CDC emphasizes that the final decision rests with Guinea-Bissau, asserting the country’s sovereignty.
* US Disagreement & Criticism of Africa CDC: The US Department of Health and Human Services (HHS) insists the trial will proceed as planned and has publicly questioned the credibility of the Africa CDC, even calling it “powerless” and “fake.” HHS claims the Africa CDC is engaged in a PR campaign. The Africa CDC director, Jean Kaseya, disputes these claims and highlights the organization’s crucial role in public health.
* Local Needs & Research Priorities: Dr. Babatunde stresses the importance of funding research that addresses the health priorities defined by african communities,rather than being driven by external funders’ interests.
* Hepatitis B Prevalence: Guinea-Bissau has a high prevalence of hepatitis B, making vaccination crucial. The World Health Organization recommends immediate vaccination at birth.

In essence, the article highlights a clash between international research agendas, ethical considerations in medical trials, and the assertion of a nation’s right to determine its own healthcare policies. It also reveals a concerning dispute between the US HHS and the Africa CDC.